Imuno Therapeutics

Right before the holiday season, we have some exciting news: our collaboration in the LETSGO program has led to a paper being accepted for the 22nd IEEE International Conference on Software Architecture ICSA 2025! At Imuno Therapeutics, we contribute our highly compute-intensive software to explore opportunities for making it more sustainable. In return, we gain insights from brilliant informatics experts, helping us build better software while contributing to a greener world. Congrats to Cyan Xiao, Chushu Gao, Pepijn van de Kamp, and Justus Bogner for their fantastic work! Together, we’re shaping smarter solutions for a greener tomorrow.

This Monday we wanted to introduce Nikolaos Bounatsos our Bioinformatics Scientist here at Imuno! Nick started his journey in bioinformatics by pursuing Computer Sciences at University of Peloponnese. He later specialized in Bioinformatics and Systems Biology at the University of Amsterdam, where he had the chance to explore better the fields of immunology and AI. He became part of the Imuno team as an intern captured by Imuno’s goal to develop effective and safe cancer therapies. Since September, he’s been contributing as a Bioinformatics Scientist, using AI to power therapeutic antibody drug discovery - a blend of technology and science. In Nick’s own words: “I’m passionate about making a real impact in healthcare by combining computational tools with biological insights!” Excited to see all the amazing things Nick will achieve next!

We’re proud to be featured in the latest edition of BiotechNews & Life Sciences 2024! In the article, we share how we're changing immunotherapy with our TCR-mimic antibodies. Plus, we highlight our collaboration with VitroScan, where we work together to refine screening technologies and create safer, more effective cancer treatments. Curious to know more? Check it out here: https://lnkd.in/emQwVrcw

It’s been a great month for Imuno! We had the opportunity to attend two leading conferences and we’re excited to share some highlights: - ENA 2024: EORTC - European Organisation for Research and Treatment of Cancer-NCI-AACR Symposium Apart from discovering the beauty of Barcelona, we had the chance to present our latest poster on an antibody-based T Cell Engager targeting p53. We also shared insights from our abstract, "On–target—prioritizing specificity during T Cell Engager discovery against peptide antigens," which was accepted and presented at the event. This gave us the perfect opportunity to highlight how we’re leveraging peptide:HLA antigens to push the boundaries of precision immunotherapy—a significant step forward in showcasing our approach. - @PEGS Europe: The Protein Engineering & Cell Therapy Summit At PEGS Europe, organized by Cambridge Healthtech Institute, a key summit for biologics and next-generation therapies, we discussed innovative protein engineering and antibody therapeutics. We shared how our platform aids the discovery of therapies that are effective and exceptionally safe. It was inspiring to see the collaborative spirit of the field and explore new ways to address complex diseases. Both events were a great reminder of the power of collaboration and knowledge-sharing in driving science forward. We were inspired by the incredible work happening across the field and even more motivated to keep innovating. So, let’s keep the conversations going! Whether it’s about pHLA targeting or the future of precision therapies, we’d love to connect. https://lnkd.in/esRryCF2

Could TCRmimic antibodies be the key to targeting hard-to-reach tumors in cancer treatment? By mimicking T-cell receptors, these antibodies target specific cancer antigens deep within cells, offering a more precise way to treat solid tumors. But is the journey as straightforward as it sounds? In our latest blog, we explore how TCRmimic antibodies are transforming cancer immunotherapy, their benefits, challenges, and the role of emerging technologies like machine learning and structural biology. Interested in reading more? Follow the link below to explore the future of cancer treatment with TCRmimic antibodies. https://lnkd.in/eYwMmEPr

We're #hiring a new Scientist to join our Antibody Engineering and Display team. Apply today or share this post with your network.

Excited to be showcasing the progress we are making to deliver precision immunotherapy. Today we will be presenting our latest poster at #ENASymp24 on an antibody based T Cell Engager targeting p53. Interested in targeting peptide:HLA antigens, come meet us. EORTC - European Organisation for Research and Treatment of Cancer AACR Journals National Cancer Institute (NCI)

The Imuno team is traveling to Barcelona for the 36th EORTC-NCI-AACR Symposium! We’re happy to share that our work has been selected for presentation at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, hosted by the EORTC - European Organisation for Research and Treatment of Cancer, the National Cancer Institute (NCI) and the American Association for Cancer Research in Barcelona, Spain from October 23 to 25! Our abstract, " On–target—prioritizing specificity during T Cell Engager discovery against peptide antigens," has been accepted, and we’ll present it at this event. This symposium is a great opportunity to start new conversations on drug development, with a focus on preclinical and early-phase studies that are paving cancer treatment. We’re excited to join experts, scientists, and industry leaders globally to share insights and explore new molecular targets. If you’ll be at ENA 2024, Jan-Jaap Verhoef, Ph.D., and Joanna Turley would love to connect! Visit them at our poster session, and discuss how specificity is driving the next wave of pHLA targeting therapies. #ENASymp24

Ιntroducing TACTICS: A Platform Targeting Specificity. As part of our series, we’re excited to highlight ImunoTX’s TACTICS platform. Keep reading here or scroll through the carousel for more insights! How It Works: Cancer cells present unique proteins via HLA molecules, distinct from those in healthy cells. Our platform identifies these “cancer signatures,” enabling us to develop therapies that precisely target a wide range of cancers. Addressing the Specificity Challenge: Conventional peptide:HLA targeting antibodies can lack specificity, leading to toxicity risks. ImunoTX's TACTICS technology mitigates this by identifying potential cross-reactive complexes, ensuring our antibodies are highly specific and safe. Driving Precision with Innovation: By leveraging Structural Biology and Artificial Intelligence, our platform rapidly develops peptide:HLA targeting antibodies. Combining AI with synthetic biology allows us to design safer therapies, faster. Why It Matters: With a focus on safety and precision, our platform is advancing therapies that reduce toxicity while delivering highly targeted cancer treatments. Interested in learning more? Click the link below! https://lnkd.in/eQ8uesaT

We’re excited to celebrate Rico Bas on his 6-month anniversary as an associate scientist at Imuno! Rico’s passion for oncology and immunology was ignited early in life, inspired by his family's background in healthcare. He pursued Biomedical Sciences at the University of Amsterdam, specializing in Infection and Immunology, and now he’s fulfilling his dream of developing innovative treatments for hard-to-treat cancers. In the 6- months he has been with us, Rico has made an impact by setting up experiments, managing lab operations, and collaborating closely with our team. “I value the supportive culture at Imuno, where continuous learning and celebrating each other’s successes are a priority”. Here’s to Rico and many more milestones ahead at Imuno!